Diversified Biotech: Pharmaceutical Companies Fill Gaps in Pipelines

Pharmaceutical companies, having placed their focus on the discovery of effective drugs, the development of such, and creation of technology to advance pharmaceutical production, face a dilemma. It is a difficult process, fraught with challenges, where results are unpredictable; the testing and trial period takes a great length of time, and there are daunting costs, all which are then transferred to the American public. In an effort to increase their production and profits, while minimizing expenses, the pharmaceutical industry is turning to the diversified biotech field as well as the development of biotech drugs.

Biotechnology is a scientific field that relates to biology, and the manipulation of living things as well as bioprocesses, branching out to many areas such as engineering, technology, medicine, and industrial fields that require bioproducts. Starting far back in human history with domestication of plants and animals to advances in agriculture through grafting and hybridization to enhance crops, it is groundbreaking in the present time with the innovations in the production of biotech drugs and the diversified biotech paths available to science. Genetic engineering, cell and tissue culture technologies, biodegradable plastic development, and research into the creation of biofuels name only a few of the new horizons opened by biotechnology. Areas of specialization vary; blue biotechnology focuses on marine and aquatic life processes and developments, green biotechology focuses on the agricultural field, red biotechnology revolves around the medical field, and white biotechnology centers on the industrial field.

As pharmaceutical companies and venture capitalists attempt to thrive, the biotechnology industry provides ample opportunities for investment. Companies are not restricted to the drug research industry alone, although biotechnology certainly will produce advancements in the pharmaceutical field, with new methods of production and sources for drugs that come from the living organisms in the environment. By being so diversified in the implications of the biotechnology field, investors will find their own economic resources building upon new discoveries.

The biofuel field is one of the most promising as an alternative to non-renewable fossil fuels, providing a bargaining chip and bolster for a weak economy. Companies that supplement their finances in the biotechnology industry are not taking a gamble but rather choosing a sensible, stable source that is a well of opportunity. In investing, they will better manage expenses, make the process of drug development more efficient and less costly to the public, and provide the American economy with a well needed boost.

Interested in Big Pharma's diversified biotech portfolios? Looking for information on biotech drugs? Check out our web site.

Article Source: http://EzineArticles.com/?expert=Jeremy_B_Thompson
http://EzineArticles.com/?Diversified-Biotech:-Pharmaceutical-Companies-Fill-Gaps-in-Pipelines&id=6526632